Société des Produits Nestlé

• NCT06953791

  Collaborator, Phase 2, Recruiting, 52 people, 1 May 2025

• NCT03833596

  Collaborator, Phase 4, Terminated, 3 people, 7 Feb 2019

• NCT02332967

  Completed, 488 people, 7 Jan 2015

• NCT01276626

  Phase 1/2, Completed, 40 people, 13 Jan 2011

• NCT00864188

  Phase 1, Completed, 207 people, 18 Mar 2009

• NCT00455247

  Phase 3, Completed, 3 Apr 2007

• Therapeutic potential of dihydronicotinamide riboside (NRH) on obesity and glucose intolerance in mice

  Employment, 25 Mar 2026

• NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations

  Employment, 23 Jan 2026

• The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans

  Employment, 15 Jan 2026

• NNMT inhibition counteracts tubular senescence and fibrosis in early stages of chronic kidney disease

  Employment, 14 Jan 2026

• TGFβ-Smad3 signaling restores cell-autonomous Srsf1-mediated splicing of fibronectin in aged skeletal muscle stem cells

  Employment, 21 Nov 2025

• Herbal terpenoids activate autophagy and mitophagy through modulation of bioenergetics and protect from metabolic stress, sarcopenia and epigenetic aging

  Employment, Shares or equity, Patents or royalties, 24 Sept 2025

Sources: pubmed.ncbi.nlm.nih.gov